Ask the MS Clinician’s Digest – Topic Learn about Multiple Sclerosis Infusion Treatments
A Video recorded interview ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ MS Views and News helps to provide information for all affected by MS Keep up…
Novartis’ MS Drug Gilenya Prevents Activation of Key Immune Cells in Study
In a recent study entitled “Myeloid cells as target of fingolimod action in multiple sclerosis,” a team of scientists investigated…
Stuart Schlossman
Emerging Therapies, Progressive MS, Wellness/Lifestyle and Other Research News from ECTRIMS Meeting
Results from clinical trials in new approaches to treating progressive and relapsing MS, wellness and lifestyle research, and myelin repair…
Stuart Schlossman
Alkermes’ Multiple Sclerosis Therapy ALKS 8700 Yields Positive Clinical Trial Data
Alkermes plc, a fully integrated global biopharmaceutical company, recently provided a regulatory update and positive clinical trial data for ALKS 8700,…
Stuart Schlossman
MS World Presents: Multiple Sclerosis NEWS FROM THE CONFERENCE CENTER
MSWORLD EXPRESS NEWS NEWS FROM THE CONFERENCE CENTER October 7th – 10th Barcelona, Spain This week…
Stuart Schlossman
Biogen reports negative data on natalizumab in Phase III multiple sclerosis trial
US biotech company Biogen (Nasdaq: BIIB) has reported negative data from the Phase III trial of natalizumab, its blockbuster drug…
Stuart Schlossman
LEMTRADA Learning Events by (USA) Zip code
Click the above banner then enter your Zip code to find live learning events near You Pertaining to a New…
Stuart Schlossman
Pharmaceutical Financial Assistance Programs
The information showing below is made possible by the National Multiple Sclerosis Society, in alphabetical srquence If you are currently…
Stuart Schlossman
Teva Pharmaceutical Industries’ COPAXONE 40 mg/mL Three-times-a-week Approved in Russia for Relapsing-Remitting Multiple Sclerosis
Russian Ministry of Health approves Teva’s COPAXONE new formulation for the treatment of RRMS Teva Pharmaceutical Industries Ltd., a leading…
Stuart Schlossman
EMD Serono Announces Publication of PRISMS-15 Years Follow-up Study Results on Rebif for Relapsing–Remitting Multiple Sclerosis
Data on long-term follow-up study on Rebif for RRMS revealed improved clinical outcomes EMD Serono, the U.S. biopharmaceutical division of…
Stuart Schlossman
